04.24.25 -- Are You Ready For 2025's Outsourcing Shift?

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches. Registration is free thanks to the support of Curia.

Investing in employee training and development is not just beneficial for the employees. It also contributes significantly to the organization’s success and competitive advantage.

Partnering with a provider that prioritizes quality and yield optimization not only ensures product safety but also helps reduce operational costs.

Here, we dissect the potency assay development process into its key steps, offering a clearer understanding of the journey.

Selecting a CDMO depends on price, geography, expertise, and other variables. While price is often a key motivation for the decision, production cost should be carefully considered. See how an independent analysis can be very helpful in making the right decision.

A sponsor’s commitment to impurity control throughout manufacturing is vital to ensuring continuous patient safety. E&Ls, nitrosamines, and PFAS are among the most critical impurities to test for.

Discover how advancements in pharmaceutical freeze-drying are reshaping the process through better product understanding, precise process control, and innovations in equipment efficiency.

Explore the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

Embrace the transformative power of predictive modeling and digital twin technology to optimize bioprocess efficiency, ensure product quality, and drive innovation in biopharmaceutical manufacturing.

Asher Biotherapeutics was seeking a CDMO that could handle Phase 2 through to commercial production, as well as taking early-stage projects in its pipeline all the way through their lifecycle.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

This interview addresses attendees' questions from a recent webinar about a new biomanufacturing site in Waltham, MA, equipped with state-of-the-art equipment.

Consider our high-quality GMP manufacturing capabilities, featuring a state-of-the-art isolator-based filling platform and extensive fill-finish capacity for vials, syringes, and cartridges.

This guide outlines essential strategies, best practices, and key considerations, highlighting why technology transfer is a vital pillar of mammalian biologic drug development and manufacturing.

GS Effex has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose.

Partner with us for fully customized, cGMP-enabling R&D services designed to accelerate your biologic from concept to commercialization.